Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity

Won Suk Lee,Hannah Yang,Hong Jae Chon,Chan Kim
DOI: https://doi.org/10.1038/s12276-020-00500-y
2020-09-01
Abstract:Abstract Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced cancers. However, the tumor microenvironment (TME) functions as a formidable barrier that severely impairs the efficacy of ICIs. While the crosstalk between tumor vessels and immune cells determines the nature of anti-tumor immunity, it is skewed toward a destructive cycle in growing tumors. First, the disorganized tumor vessels hinder CD8 + T cell trafficking into the TME, disable effector functions, and even kill T cells. Moreover, VEGF, the key driver of angiogenesis, interferes with the maturation of dendritic cells, thereby suppressing T cell priming, and VEGF also induces TOX-mediated exhaustion of CD8 + T cells. Meanwhile, a variety of innate and adaptive immune cells contribute to the malformation of tumor vessels. Protumoral M2-like macrophages as well as T H 2 and Treg cells secrete pro-angiogenic factors that accelerate uncontrolled angiogenesis and promote vascular immaturity. While CD8 + T and CD4 + T H 1 cells suppress angiogenesis and induce vascular maturation by secreting IFN-γ, they are unable to infiltrate the TME due to malformed tumor vessels. These findings led to preclinical studies that demonstrated that simultaneous targeting of tumor vessels and immunity is a viable strategy to normalize aberrant vascular-immune crosstalk and potentiate cancer immunotherapy. Furthermore, this combination strategy has been evidently demonstrated through recent pivotal clinical trials, granted approval from FDA, and is now being used in patients with kidney, liver, lung, or uterine cancer. Overall, combining anti-angiogenic therapy and ICI is a valid therapeutic strategy that can enhance cancer immunity and will further expand the landscape of cancer treatment.
biochemistry & molecular biology,medicine, research & experimental
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is the poor efficacy of immune checkpoint inhibitors (ICIs) in tumor immunotherapy. Specifically, the paper explores how the vascular - immune interactions in the tumor microenvironment (TME) affect the efficacy of ICIs, and proposes that the combination of anti - angiogenic therapy and immune checkpoint blockade therapy can effectively improve the effect of cancer immunotherapy. ### Background of the paper - **Immune checkpoint inhibitors (ICIs)**: ICIs have made revolutionary progress in the treatment of advanced cancers. By re - activating dysfunctional or exhausted cytotoxic T cells (CTLs), they exert powerful anti - tumor effector functions, achieving effective and long - lasting control of previously refractory cancers. - **Tumor microenvironment (TME)**: Despite the remarkable progress of ICIs, only 20% - 30% of cancer patients respond to ICIs treatment. The TME is considered one of the major obstacles that seriously affect the efficacy of ICIs. The interaction between tumor blood vessels and pro - tumor immune cells within the TME forms a vicious cycle, which seriously interferes with anti - tumor immunity and promotes tumor progression. ### Main problems - **Vascular - immune interactions**: Abnormal tumor neovascularization not only hinders CTLs from entering the tumor, but also impairs the effector function of T cells and even leads to T - cell apoptosis. In addition, vascular endothelial growth factor (VEGF) inhibits the maturation of dendritic cells (DCs) through multiple mechanisms, resulting in impaired T - cell priming and inducing TOX - mediated CD8+ T - cell exhaustion. - **Immunosuppression**: Pro - tumor M2 - like macrophages as well as TH2 and Treg cells secrete pro - angiogenic factors, accelerating disordered angiogenesis and promoting vascular immaturity. Although CD8+ T and CD4+ TH1 cells inhibit angiogenesis and induce vascular maturity by secreting IFN - γ, they cannot penetrate the TME due to the abnormal tumor blood vessels. ### Solutions - **Combination therapy strategy**: The paper proposes that simultaneously targeting tumor blood vessels and the immune system can normalize abnormal vascular - immune interactions and enhance the effect of cancer immunotherapy. This combination therapy strategy has been verified in multiple clinical trials and has been approved by the FDA, and is currently used for the treatment of patients with kidney, liver, lung or uterine cancer. ### Conclusions - **Vascular normalization**: Moderate anti - angiogenic therapy can achieve vascular normalization, improving the delivery of oxygen, drugs and anti - tumor immune cells, rather than overly destroying blood vessels and causing intratumoral hypoxia. - **Remodeling of the immune microenvironment**: The combination of anti - angiogenic therapy and ICIs can reshape the immune microenvironment through vascular normalization and the formation of intratumoral high endothelial venules (HEVs), further strengthening the anti - tumor immune response and overcoming resistance to cancer immunotherapy. Through these studies, the paper provides a strong theoretical basis for the combination of anti - angiogenic therapy and ICIs, opening up new avenues for improving the effect of cancer immunotherapy.